Skip to main content
SpringerLink
Log in

Phase 2 Clinical Development in Treating Chronic Diseases

  • Clinical Trials
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

Abstract

Phase 2 is the most critical stage in the entire clinical development process of a new drug because results from this phase are used to make go or no-go decisions for phase 3, and phase 3 consumes the greatest resources in new drug R&D. This is especially true in the development of drugs to treat chronic diseases. In this article we discuss the background, objectives, and risks in phase 2 development. One of the key challenges is how to design the first dose-ranging clinical trial. A practical application is suggested and two examples are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ting N. Introduction and new drug development process. In: Ting N. Dose Finding in Drug Development. New York: Springer; 2006:1–17.

    Chapter  Google Scholar 

  2. Ting N. General considerations in dose-response study designs. In: Ting N. Dose Finding in Drug Development. New York: Springer; 2006:89–103.

    Chapter  Google Scholar 

  3. Grieve A. Discussion of the “white paper of the PhRMA Working Group on adaptive dose-ranging designs.” J Biopharm Stat. 2007;17:997–1004.

    Article  CAS  Google Scholar 

  4. Proschan MA, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer: 2007.

    Google Scholar 

  5. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70: 659–663.

    Article  Google Scholar 

  6. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002;58:823–831.

    Article  Google Scholar 

  7. Bauer P, Keiser M. Combining different phases in the development of medical treatments within a single trial. Stat Med. 1999;18:1833–1848.

    Article  CAS  Google Scholar 

  8. Hamlett A, Ting N, Hanumara C, Finman JS. Dose spacing in early dose response clinical trial designs. Drug Inf J. 2002;36:855–864.

    Article  Google Scholar 

  9. Ting N. Confirm and explore: a stepwise approach to clinical trial designs. Drug Inf J. 2008; 42:545–554.

    Article  Google Scholar 

  10. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA, and the ASTIN Study Investigators. ASTIN: an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003; 34:2543–2544.

    Article  CAS  Google Scholar 

  11. Ting N. Practical and statistical considerations in designing an early phase II osteoarthritis clinical trial: a case study. Comm Stat Theory Meth. 2010;38:3282–3296.

    Article  Google Scholar 

  12. Bellamy N, Campbell J, Stevens J, Pilch L, Stewart C, Mahmood Z. Validation study of a computerized version of the Western Ontario and McMaster Universities VA 3.0 Osteoarthritis Index. J Rheumatol. 1997;24:2413–2415.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boehringer-Ingelheim Pharmaceuticals Inc, USA

    Naitee Ting

Authors
  1. Naitee Ting
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naitee Ting.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ting, N. Phase 2 Clinical Development in Treating Chronic Diseases. Ther Innov Regul Sci 45, 431–442 (2011). https://doi.org/10.1177/009286151104500405

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/009286151104500405

Key Words

Search

Navigation